These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 17453220)

  • 1. Scleroderma -- news to tell.
    Eckes B; Hunzelmann N; Moinzadeh P; Krieg T
    Arch Dermatol Res; 2007 Jun; 299(3):139-44. PubMed ID: 17453220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The controversial role of tumor necrosis factor alpha in fibrotic diseases.
    Distler JH; Schett G; Gay S; Distler O
    Arthritis Rheum; 2008 Aug; 58(8):2228-35. PubMed ID: 18668576
    [No Abstract]   [Full Text] [Related]  

  • 3. The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis?
    Yamamoto T
    Arch Dermatol Res; 2006 Feb; 297(8):333-44. PubMed ID: 16402183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scleroderma--pathophysiology.
    Yamamoto T
    Eur J Dermatol; 2009; 19(1):14-24. PubMed ID: 19059831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The control of fibrosis in systemic sclerosis: a strategy involving extracellular matrix, cytokines, and growth factors.
    LeRoy EC
    J Dermatol; 1994 Jan; 21(1):1-4. PubMed ID: 8157815
    [No Abstract]   [Full Text] [Related]  

  • 6. Understanding systemic sclerosis through gene expression profiling.
    Pendergrass SA; Whitfield ML; Gardner H
    Curr Opin Rheumatol; 2007 Nov; 19(6):561-7. PubMed ID: 17917536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelin receptor selectivity: evidence from in vitro and pre-clinical models of scleroderma.
    Shiwen X; Leask A; Abraham DJ; Fonseca C
    Eur J Clin Invest; 2009 Jun; 39 Suppl 2():19-26. PubMed ID: 19335743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel insights in the pathogenesis of systemic sclerosis.
    Radstake TR
    Expert Rev Clin Immunol; 2011 Jul; 7(4):389-90. PubMed ID: 21790277
    [No Abstract]   [Full Text] [Related]  

  • 9. Scleroderma: from cell and molecular mechanisms to disease models.
    Abraham DJ; Varga J
    Trends Immunol; 2005 Nov; 26(11):587-95. PubMed ID: 16168711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular pathways as novel therapeutic targets in systemic sclerosis.
    Trojanowska M; Varga J
    Curr Opin Rheumatol; 2007 Nov; 19(6):568-73. PubMed ID: 17917537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proceedings of the third international workshop on scleroderma research.
    Black CM; Korn JH
    Matrix Biol; 1995 Dec; 14(9):699-704. PubMed ID: 8785584
    [No Abstract]   [Full Text] [Related]  

  • 12. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis.
    Distler JH; Jüngel A; Pileckyte M; Zwerina J; Michel BA; Gay RE; Kowal-Bielecka O; Matucci-Cerinic M; Schett G; Marti HH; Gay S; Distler O
    Arthritis Rheum; 2007 Dec; 56(12):4203-15. PubMed ID: 18050252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of pulmonary fibrosis in systemic sclerosis: light at the end of the tunnel?
    Wollheim FA
    Arthritis Rheum; 2007 Jan; 56(1):9-12. PubMed ID: 17195185
    [No Abstract]   [Full Text] [Related]  

  • 14. Altered expression of calreticulin during the development of fibrosis.
    Kypreou KP; Kavvadas P; Karamessinis P; Peroulis M; Alberti A; Sideras P; Psarras S; Capetanaki Y; Politis PK; Charonis AS
    Proteomics; 2008 Jun; 8(12):2407-19. PubMed ID: 18563736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of severity and subtype of fibrosing disease using model informed by inflammation and extracellular matrix gene index.
    Cheikhi AM; Johnson ZI; Julian DR; Wheeler S; Feghali-Bostwick C; Conley YP; Lyons-Weiler J; Yates CC
    PLoS One; 2020; 15(10):e0240986. PubMed ID: 33095822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Connective tissue metabolism in scleroderma, including cytokines.
    Unemori EN; Amento EP
    Curr Opin Rheumatol; 1996 Nov; 8(6):580-4. PubMed ID: 9018463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc?
    Abraham D
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v8-9. PubMed ID: 18784153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel treatment approaches to fibrosis in scleroderma.
    Distler J; Distler O
    Rheum Dis Clin North Am; 2008 Feb; 34(1):145-59; vii. PubMed ID: 18329537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging targets for the treatment of scleroderma.
    Leask A
    Expert Opin Emerg Drugs; 2012 Jun; 17(2):173-9. PubMed ID: 22533795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathophysiology of systemic sclerosis (scleroderma).
    Rosendahl AH; Schönborn K; Krieg T
    Kaohsiung J Med Sci; 2022 Mar; 38(3):187-195. PubMed ID: 35234358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.